ABVXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as AAVXF
Abivax S.A.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 23, 2026
$87.49−0.64 (-0.73%)
Close on Oct 19, 2026
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
55M
Shares held, 13F filers
Institutional holders
302
91 new, 40 sold out
Net institutional buying
6M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Sofinnova Crossover I SLP | 9,599,478 | 11.40% | 13D (active) amendment | Jul 23, 2025 |
| Cedric Moreau | 8,399,478 | 9.40% | 13D (active) amendment | Oct 28, 2025 |
| Joseph Anderson | 7,794,478 | 11.00% | 13D (active) amendment | Feb 14, 2025 |
| Chen Yu | 6,007,834 | 7.00% | 13G (passive) amendment | Jun 30, 2026 |
| Invus Public Equities, L.P. | 5,403,985 | 8.50% | 13G (passive) | Sep 2, 2022 |
| Raymond Debbane | 4,825,759 | 6.00% | 13G (passive) amendment | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ABVX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| TCG Crossover Management, LLC | 6,007,834 | – | $800.60M | −473,251 | 19.24% |
| Darwin Global Management, Ltd. | 3,621,583 | – | $348.22M | +152,926 | 9.26% |
| Helikon Investments Ltd | 2,787,131 | – | $371.41M | +1,773,807 | 11.10% |
| Vestal Point Capital, LP | 2,349,443 | – | $313.09M | +849,443 | 7.32% |
| Jupiter Topco LLC | 1,913,933 | – | $255.13M | New | 0.10% |
| UBS Group AG | 1,844,918 | – | $245.85M | −2,702,488 | 0.03% |
| ADAR1 Capital Management, LLC | 1,804,703 | – | $240.49M | +410,684 | 11.01% |
| Caligan Partners LP | 1,557,924 | – | $207.61M | +96,000 | 9.77% |
| Citadel Advisors LLC | 1,438,352 | – | $191.67M | +894,014 | 0.02% |
| Morgan Stanley | 1,432,185 | – | $190.85M | −272,773 | 0.01% |
| Westfield Capital Management Co LP | 1,309,825 | – | $174.55M | −13,113 | 0.57% |
| Ra Capital Management, L.P. | 1,132,557 | – | $150.92M | New | 1.31% |
| Norges Bank | 1,100,000 | – | $146.59M | New | 0.01% |
| Susquehanna International Group, Llp | 1,053,896 | – | $140.44M | +672,614 | 0.01% |
| Logos Global Management LP | 1,024,000 | – | $136.46M | +349,000 | 5.87% |
| Octagon Capital Advisors LP | 993,000 | – | $132.33M | +316,000 | 11.89% |
| Bank Of America Corp /De/ | 971,439 | – | $129.45M | +235,710 | 0.01% |
| Eversept Partners, LP | 913,880 | – | $121.78M | −20,543 | 6.32% |
| Goldman Sachs Group Inc | 792,712 | – | $105.64M | +443,915 | 0.01% |
| Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. | 765,332 | – | $101.99M | −583 | 5.59% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 302 | 55M | 91 / 98 | 100 / 40 | 18M | 13M |
| Q1 2026 | 254 | 50M | 53 / 112 | 74 / 44 | 6M | 12M |
| Q4 2025 | 247 | 56M | 107 / 76 | 50 / 24 | 12M | 8M |
| Q3 2025 | 165 | 52M | 130 / 16 | 17 / 8 | 33M | 11M |
| Q2 2025 | 43 | 31M | 6 / 16 | 11 / 9 | 2M | 4M |
| Q1 2025 | 46 | 32M | 8 / 18 | 11 / 10 | 5M | 3M |
| Q4 2024 | 48 | 30M | 14 / 14 | 9 / 6 | 5M | 3M |
| Q3 2024 | 40 | 27M | 4 / 17 | 12 / 2 | 2M | 4M |
| Q2 2024 | 38 | 29M | 4 / 13 | 13 / 2 | 7M | 3M |
| Q1 2024 | 36 | 25M | 12 / 9 | 7 / 6 | 4M | 2M |
| Q4 2023 | 30 | 23M | 30 / 0 | 0 / 0 | 23M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of ABVX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Alger Focus Equity Fund | 607,577 | – | $75.90M | 1.07% | Jul 31, 2026 |
| iShares Biotechnology ETF | 458,824 | – | $61.14M | 0.67% | Jun 30, 2026 |
| Eventide Healthcare & Life Sciences Fund | 394,782 | – | $52.61M | 2.94% | Jun 30, 2026 |
| Alger Spectra Fund | 334,177 | – | $41.75M | 0.97% | Jul 31, 2026 |
| Harbor Small Cap Growth Fund | 296,560 | – | $37.05M | 1.39% | Jul 31, 2026 |
| Alger Capital Appreciation Institutional Fund | 259,984 | – | $32.48M | 0.94% | Jul 31, 2026 |
| Select Biotechnology Portfolio | 255,300 | – | $33.86M | 0.64% | May 31, 2026 |
| Alger Capital Appreciation Fund | 208,404 | – | $26.03M | 0.95% | Jul 31, 2026 |
| Janus Henderson Global Life Sciences Fund | 179,100 | – | $23.87M | 0.41% | Jun 30, 2026 |
| Fidelity Growth Company Fund | 139,580 | – | $18.51M | 0.02% | May 31, 2026 |
| Alger Small Cap Focus Fund | 116,210 | – | $14.52M | 1.70% | Jul 31, 2026 |
| SmallCap Fund | 111,567 | – | $13.94M | 0.67% | Jul 31, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 109,661 | – | $14.61M | 0.10% | Jun 30, 2026 |
| Franklin Biotechnology Discovery Fund | 109,022 | – | $13.62M | 1.18% | Jul 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 104,054 | – | $13.87M | 0.12% | Jun 30, 2026 |
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Crossover I. SLP Sofinnova Affiliate | Jan 8, 2026 | 1,000,000 | $133.70M | Jan 8, 2026 | Private Placement |
| Crossover I. SLP Sofinnova Affiliate | Oct 28, 2025 | 1,200,000 | $111.30M | Oct 28, 2025 | Purchased in IPO |